1809010-52-3
Chemical Structure
Berotralstat dihydrochloride
Synonym(s): BCX7353 dihydrochloride
- CAS No.: 1809010-52-3
- Formula:C30H28Cl2F4N6O
- Molecular Weight:635.48
IUPAC Name: (R)-1-(3-(aminomethyl)phenyl)-N-(5-((3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride
InChIKey: XFZLBLTUANGZBD-QDSLRZTOSA-N
SMILES: O=C(C1=CC(C(F)(F)F)=NN1C2=CC(CN)=CC=C2)NC3=CC([C@@H](C4=CC(C#N)=CC=C4)NCC5CC5)=CC=C3F.[H]Cl.[H]Cl
Biological Activity: Berotralstat dihydrochloride (BCX7353 dihydrochloride) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Berotralstat dihydrochloride | 98.67% | Berotralstat dihydrochloride (BCX7353 dihydrochloride) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Berotralstat dihydrochloride (Standard) | ≥98% | Berotralstat dihydrochloride (Standard) is the analytical standard of Berotralstat (dihydrochloride) (HY-109127A). This product is intended for research and analytical applications. Berotralstat dihydrochloride (BCX7353 dihydrochloride) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Zuraw B, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial [published online ahead of print, 2020 Oct 21]. J Allergy Clin Immunol. 2020;S0091-6749(20)31484-6. [Content Brief]
- [2]. Richard E. Kast, et al. Reducing Brain Edema Using Berotralstat, an Inhibitor of Bradykinin, Repurposed as Treatment Adjunct in Glioblastoma. Neuroglia. 2024, 5(3), 223-233.
